Major Announcements - Glacier Network plans to sign an exclusive overseas agency agreement with Chengdu Time Race Technology Co., Ltd., a 14% owned affiliate, for the promotion and operation of "Magic War" [3] - Nairui Radar intends to acquire 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of share issuance and cash payment [4] - Howie Group's wholly-owned subsidiary, Shaoxing Wehao, plans to invest 200 million yuan in a private equity fund, holding an 18.39% stake [5] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [6] - Yanzhou Coal Mining plans to acquire 100% equity of a high-end support manufacturing company for 345 million yuan, constituting a related party transaction [7] Termination of Cooperation - Jincheng Pharmaceutical has decided to terminate its intention to cooperate with Dutch company Giskit regarding the exclusive commercialization rights of ExEm® Foam in China due to lack of substantial progress in negotiations [9] Mining License Acquisition - Hunan Gold's subsidiary Xinshao Siwei has obtained a mining license for the Xinshao County Tanxi Tungsten Mine, with an annual production capacity of 990,000 tons [10] Share Buybacks - Visionox has initiated a share buyback of 1.6607 million shares for approximately 15 million yuan, with a maximum price of 14.8 yuan per share [11] - Koli completed a share buyback amounting to 10.9949 million yuan, acquiring 845,700 shares at prices between 12.89 and 13.13 yuan per share [12] - Maide Medical's chairman proposed a share buyback plan with a total amount between 20 million and 40 million yuan [13] Shareholding Changes - Funeng Technology's shareholder plans to reduce its stake by up to 1.6816%, totaling no more than 20.551 million shares [14] - Aerospace Hongtu's director intends to sell up to 5,000 shares due to personal financial needs [15] Project Wins - Anhui Construction has won two projects with a total bid price of 2.603 billion yuan, with the company's share being approximately 600 million yuan [16][17]

Major Events - Glacier Network plans to sign an exclusive overseas agency agreement with Chengdu Time Race Technology Co., Ltd., a company in which it holds a 14% stake, for the promotion and operation of "Magic War" [4] - Nairui Radar intends to acquire 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of issuing shares and cash [5] - Howey Group's wholly-owned subsidiary, Shaoxing Wehao, plans to invest 200 million yuan in a private equity fund [6][7] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [8] - Yanzhou Coal Mining plans to acquire 100% equity of a high-end support manufacturing company for 345 million yuan, constituting a related party transaction [9] - Jincheng Pharmaceutical has decided to terminate its intention to cooperate with Dutch company Giskit regarding exclusive commercialization rights for a drug in China due to lack of substantial progress [10] - Hunan Gold's subsidiary obtained a mining license for tungsten, magnetite, and silver with an annual production capacity of 990,000 tons [11] Share Buybacks - Visionox completed its first share buyback of 1.6607 million shares for approximately 15 million yuan, with a maximum price of 14.8 yuan per share [12] - Koli completed a share buyback of 10.9949 million yuan, acquiring 845,700 shares at prices between 12.89 and 13.13 yuan per share [13][14] - Maide Medical's chairman proposed a share buyback plan with a total amount between 20 million and 40 million yuan [15] Shareholding Changes - Funeng Technology's shareholder plans to reduce its stake by up to 1.6816%, totaling approximately 20.551 million shares [16] - Aerospace Hongtu's director plans to reduce his holdings by 5,000 shares due to personal financial needs [17] Major Contracts - Anhui Construction won two projects with a total bid price of 2.603 billion yuan, with the company's share being approximately 600 million yuan for each project [18]

Core Viewpoint - Jincheng Pharmaceutical has decided to terminate its intended cooperation project with Giskit Pharma B.V. due to insufficient progress in negotiations and lack of consensus on key issues [1] Summary by Relevant Sections Cooperation Agreement - In August 2024, Jincheng Pharmaceutical and Giskit began negotiations for exclusive commercialization rights in China for Giskit's drug ExEm Foam, which evaluates tubal patency in women with infertility [1] - In September 2024, both parties agreed to extend exclusive negotiations until November 15, 2024, to reach a final agreement [1] - On November 18, 2024, Jincheng disclosed that negotiations on key terms for exclusive distribution were still ongoing after the expiration of the exclusivity period [1] Decision to Terminate - Jincheng Pharmaceutical stated that the cooperation framework agreement was only a preliminary arrangement, and no formal cooperation agreement was signed [1] - The negotiations did not progress as expected, and no substantial advancements were made regarding the cooperation project [1] - After careful consideration of its development strategy and operational circumstances, the company decided to terminate the intended cooperation project [1]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - The company has decided to terminate the intention to cooperate with Giskit Pharma B.V. regarding the commercialization rights of ExEm Foam in China due to lack of substantial progress in negotiations [1] Group 1: Cooperation Agreement - The company announced a cooperation framework agreement with Giskit Pharma B.V. for exclusive commercialization rights of ExEm Foam in China [1] - The cooperation framework agreement is an intention-based arrangement, and no formal cooperation agreement has been signed [1] - Negotiations for the cooperation have not progressed as expected, and key issues remain unresolved [1] Group 2: Strategic Decision - The company has conducted a careful review based on its development strategy and operational circumstances [1] - As a result of the review, the company has decided to terminate the intention to cooperate on the project [1]

Core Points - Jin Cheng Pharmaceutical (300233) announced on November 27 that it has been negotiating exclusive commercialization rights for ExEm Foam, a drug owned by Dutch company Giskit, which is used for evaluating tubal patency in women with infertility in China [1] - Both parties have agreed to continue exclusive negotiations to reach a cooperation agreement and have extended the negotiation period until November 15, 2024 [1] - Despite the intention to cooperate, the negotiation progress has not met expectations, and no substantial agreement has been reached on key issues, leading the company to decide to terminate the intended cooperation project [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-080 2024 年 9 月 30 日，公司披露了《关于签署合作框架协议的进展公告》（公告 编号：2024-072），经双方协商一致，同意继续开展排他性谈判以争取达成一致的 合作方案并签署最终协议，同意延长排他性谈判期限至 2024 年 11 月 15 日。2024 年 11 月 18 日，公司披露了《关于签署合作框架协议的进展公告》（公告编号： 2024-079），经双方协商一致，排他性谈判期限届满后，公司与 Giskit 仍将就独 家经销合作的关键条款进行磋商。 二、终止意向性合作的原因 《合作框架协议》属于意向性约定，双方未就相关合作事项签署正式的合作协 议。自上述意向性合作协议签署后，合作事项的谈判进展不及预期，且各方未就本 次合作项目的关键问题达成一致意见，至今未有实质性进展。公司结合发展战略及 经营等实际情况，经审慎研究决定终止上述意向性合作项目。 三、对公司的影响 双方签署的《合作框架协议》仅为开展业务合作的框架性、意向性协议。各方 并未签署正式投资协议及其他具有法律约束力的文件。本次意向性合作事项的终止 不会对公司财务状况和生产经 ...

Core Viewpoint - Jincheng Pharmaceutical's stock has shown a significant increase of 41.23% year-to-date, despite recent declines in the last five, twenty, and sixty trading days [1][2]. Company Overview - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [2]. - The revenue composition of Jincheng Pharmaceutical includes: 34.59% from formulation products, 26.61% from other pharmaceutical chemical products, 21.88% from cephalosporin side chain active esters, and 16.92% from biopharmaceuticals and specialty APIs [2]. Financial Performance - For the period from January to September 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.577 million yuan, down 79.10% year-on-year [2]. - The company has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jincheng Pharmaceutical had 26,700 shareholders, an increase of 0.46% from the previous period, with an average of 13,903 circulating shares per shareholder, a decrease of 0.46% [2][3]. - Notable shareholders include the fourth-largest shareholder, Fortune Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and the eighth-largest shareholder, Hong Kong Central Clearing Limited, holding 3.336 million shares, which decreased by 2.135 million shares from the previous period [3].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shandong Jincheng Biopharmaceutical Co., Ltd., has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for glutathione active pharmaceutical ingredient [1] Group 1 - The CEP certificate indicates that the glutathione product meets the European Pharmacopoeia standards, which is crucial for market access in Europe [1] - This approval may enhance the company's competitive position in the biopharmaceutical market, particularly in Europe [1] - The receipt of the CEP certificate is expected to facilitate the company's export activities and potentially increase revenue from international markets [1]

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]